Kisspeptin research: the mechanism and the human trial record, read in full.

Before the details

Kisspeptin research has a tidy logical spine, so it is worth laying it out plainly before the studies. The chain is: kisspeptin switches on GnRH-releasing neurons in the brain, GnRH switches on the pituitary, the pituitary releases LH and FSH, and those switch on the ovaries or testes. Most of the science is about confirming each link and learning how to work the switch.

The story moves from the inside out. First, genetics showed the switch is essential — break it and puberty fails. Then single-neuron experiments showed exactly how kisspeptin makes a brain cell fire. Then human studies showed that giving kisspeptin to people reliably raises LH (the standard readout that the signal is working), and that the way you give it — a bolus versus a constant drip — changes everything because of desensitization. The newest work pushes into two frontiers: easier delivery (a nasal spray) and the brain's sexual-desire circuitry. Technical terms like LH (luteinizing hormone) and GnRH (gonadotropin-releasing hormone) are glossed on first use below.

Mechanism: how kisspeptin excites a GnRH neuron

Kisspeptin binds KISS1R, a Gq/11-coupled receptor on hypothalamic GnRH neurons, and sets off a phospholipase C (an enzyme that triggers an internal calcium signal) cascade: IP3 releases stored calcium, potassium channels close, non-selective cation channels open, and the neuron depolarizes and fires ^[2]. Applied directly to mouse GnRH neurons, kisspeptin depolarized them by 6 ± 1 mV and increased firing rate by 87 ± 4% in about three-quarters of the cells tested ^[2].

That this happens directly on GnRH neurons through KISS1R is well established: the receptor co-localizes with GnRH neurons, kisspeptin fails to raise LH or FSH in receptor-knockout mice, and central administration in sheep triggers GnRH release into the cerebrospinal fluid with a matching rise in blood LH ^[14]. The pulse itself is thought to be generated by KNDy neurons of the arcuate nucleus — cells that co-release kisspeptin, neurokinin B, and dynorphin — acting as the timer for the whole axis.

Kisspeptin-10 in men: LH, pulse frequency, and testosterone

In healthy men, intravenous kisspeptin-10 produced maximal LH stimulation at a 1 microgram/kg bolus, raising LH from 4.1 to 12.4 IU/L at 30 minutes ^[3]. Continuous infusion at 1.5 micrograms/kg/h lifted mean LH from 5.2 to 14.1 IU/L and increased the frequency of LH pulses from 0.7 to 1.0 per hour, while a higher 4 micrograms/kg/h infusion raised serum testosterone from 16.6 to 24.0 nmol/L ^[3]. These are dose-dependent, reproducible effects, and they establish kisspeptin-10 as a potent LH stimulator in men. Doses here are reported strictly as what was administered to which population by which route — not as a recommendation.

Fertility: hypothalamic amenorrhea and IVF

In women whose periods had stopped from hypothalamic suppression, a continuous infusion of kisspeptin-54 (0.01 to 1.00 nmol/kg/h) restored pulsatile LH secretion: pulses rose from 1.6 to 5.0 per 8 hours (about three-fold) and the hormone released per pulse rose roughly six-fold versus vehicle — though the highest dose produced tachyphylaxis over the infusion ^[5]. In a Phase 2 randomized trial of 60 women at high risk of ovarian hyperstimulation syndrome (OHSS, a serious IVF complication), a single subcutaneous kisspeptin-54 dose triggered egg maturation in 95% of women with no case of moderate, severe, or critical OHSS; the highest live-birth rate, 62%, followed the 9.6 nmol/kg dose ^[6]. Subcutaneous infusion also raised LH and FSH in healthy women in the early follicular phase, with the LH response tracking baseline estradiol ^[10].

The sexual-brain trials

The lens this site follows is the brain. In a randomized double-blind crossover trial in 32 men with hypoactive sexual desire disorder, intravenous kisspeptin-54 modulated activity across the sexual-processing brain networks and increased penile tumescence by up to 56% over placebo, with heightened self-reported sexual desire and no adverse events ^[8]. A companion trial in 32 premenopausal women with the same condition found kisspeptin-54 modulated neural processing in attraction and sexual-aversion circuitry, with effects that correlated with each participant's baseline sexual-distress score ^[9]. In male mice, selectively activating kisspeptin neurons in a limbic region of the brain increased interest in a female, lengthened social interaction, and reduced anxiety-like behavior ^[11]. These findings are why kisspeptin is studied as a candidate for desire disorders that act on the brain rather than on blood flow.

Newer data: intranasal delivery and the clinical landscape

In 2025, intranasal kisspeptin-54 rapidly stimulated LH release in healthy men (+4.4 IU/L), healthy women (+1.4 IU/L), and women with hypothalamic amenorrhea (+4.4 IU/L) with no adverse events, and the nasal-spray formulation stayed stable for up to 60 days at 4°C — the first clinical demonstration of an effective non-invasive route ^[16]. A 2025 systematic review of kisspeptin's clinical status identified 29 interventional trials studying it across amenorrhea, puberty regulation, ovarian function, trophoblast invasion, fertility regulation, parturition, and lactation, noting considerably fewer side effects than comparators — while confirming that no kisspeptin product is regulatory-approved ^[7]. A 2025 trial in 95 participants found kisspeptin robustly raised LH but did not significantly alter anxiety, cortisol, blood pressure, or heart rate ^[11]. The picture is a deep, consistent Phase 1/2 record from a small number of centers, awaiting larger independent and Phase 3 work.